Kyntra Bio will announce its first quarter 2026 financial results on May 11 after market close, followed by a conference call at 5:00 PM Eastern Time to discuss the company's performance and business updates. The biopharmaceutical company focuses on oncology and rare disease therapies, with products like Roxadustat approved for anemia in chronic kidney disease and ongoing trials for cancer treatments. Investors can access the webcast live or via replay on Kyntra Bio's website. This update is important for stakeholders tracking the company's progress in drug development and market expansion.
RootsFi has integrated Cap's stcUSD as a primary yield source on the Tempo payment network, allowing users' balances to earn native yield backed by financial guarantees. This integration combines Tempo's fast Layer 1 payment infrastructure, RootsFi's...
MLCommons announced the MLPerf Training v6.0 benchmark results, introducing two new benchmarks—DeepSeek V3 and GPT-OSS 20B—that highlight the industry's shift toward sparse computation using Mixture-of-Experts (MoE) architectures. These benchmarks te...
AppFolio has enhanced its Performance Platform with new AI-driven features across leasing, accounting, and resident operations, integrating Anthropic’s Claude AI to automate complex workflows. These updates include automated invoice processing, multi...
Metallium Limited has successfully operated three Flash Joule Heating units simultaneously at its Texas facility, marking a key milestone in scaling its proprietary technology. The operation achieved 83% availability and nearly 100% utilization, exce...
Air Comm, a leading provider of wireless communication and security technology, has opened a new office in Farmers Branch, Texas, expanding its presence in the Dallas-Fort Worth area. This new location enhances Air Comm's ability to offer faster loca...
